Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 16/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499446 | 0.92 | SCN9A (0.47) | SCN9AITKSCN10AALOX5APFEN1 | |
| SCHEMBL6498000 | 0.90 | ALOX5AP (0.39) | SCN9AITKALOX5APFEN1IRAK4 | |
| SCHEMBL6465874 | 0.88 | ITK (0.44) | SCN9AITKIRAK4 | |
| SCHEMBL6504829 | 0.86 | SCN9A (0.53) | SCN9AITKSCN10A | |
| SCHEMBL6470662 | 0.86 | ITK (0.45) | SCN9AITKIRAK4 | |
| SCHEMBL6500256 | 0.85 | ITK (0.40) | SCN9AITKALOX5APFEN1 | |
| SCHEMBL6470220 | 0.85 | ITK (0.38) | SCN9AITKALOX5APFEN1IRAK4 | |
| SCHEMBL6467409 | 0.85 | FEN1 (0.48) | SCN9AITKALOX5APFEN1 | |
| SCHEMBL6507806 | 0.84 | SCN9A (0.57) | SCN9AITKSCN10AIRAK4 | |
| SCHEMBL6502983 | 0.84 | ITK (0.41) | SCN9AITKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005037797-A1 | SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | SCN9A 4159/4885ITK 4236/4885SCN10A 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.